This trial is evaluating whether Inotuzumab Ozogamicin will improve 1 primary outcome and 5 secondary outcomes in patients with Leukemia, Lymphocytic, Acute, L1. Measurement will happen over the course of Enrollment to end of treatment up to 9 months.
This trial requires 26 total participants across 1 different treatment group
This trial involves a single treatment. Inotuzumab Ozogamicin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Patients whose tumors have a chromosomal abnormality called 13q14, a translocation involving chromosome 13, often develop CLL after a year from therapy. Inotuzumab ozogamicin is used to treat these patients because this type of chromosomal abnormality does not appear to be responsive to conventional chemotherapy, due to its lack of activity against B cells. However, when patients have 13q14 abnormalities, they almost always respond to inotuzumab ozogamicin. It is therefore important to know whether a patient has 13q14 before starting personalized therapy with inotuzumab ozogamicin." - Anonymous Online Contributor
"The current data suggest that this regimen is active in patients with B-NHL. However, further study is required to evaluate its utility in elderly patients with CLL or SLL, and to establish its role in MCL." - Anonymous Online Contributor
"The majority of patients treated with iota alone experienced an overall response rate of >25%, including responders whose disease had not responded to previous treatments. A trend toward improved outcomes was observed in patients receiving iota plus paclitaxel over those receiving iota alone. Iota monotherapy should be considered in refractory/ relapsed follicular lymphoma." - Anonymous Online Contributor
"They usually begin within 2 years after their initial diagnosis (mean 8.7 months). For patients who present with bulky lymphoma (>10 cm dilation), they are more likely to have advanced stage disease at presentation (stage 3 or 4) than those presenting with nonbulky lymphoma (<10 cm dilation). Patients with a history of AIDS were more likely to have advanced lymphoma stage at presentation." - Anonymous Online Contributor
"Because lymphomas are generally diagnosed at a younger age than cancers, we estimated the average age of diagnosis for lymphoma as 48 years. When comparing the mean age of diagnosis with the mean age of death, we found that the average age of dying was 65 years. These data provide some insight into the demographics of lymphoma. With the exception of HL, the number of cases of each type of lymphoma increases with increasing age." - Anonymous Online Contributor
"Inotuzumab ozogamicin was shown to have superior efficacy compared to a placebo for patients with refractory B-cell lymphoma. Furthermore, this study demonstrated that combination of inotuzumab ozogamicin and rituximab showed similar superiority to inotuzumab ozogamicin alone. This trial demonstrates that inotuzumab ozogamicin is a promising drug candidate for treatment of B-cell lymphoma, and further studies are required to evaluate its most appropriate use." - Anonymous Online Contributor
"Inotuzumab ozogamicin was well tolerated and associated with high response rates in patients with relapsed or refractory B-cell lymphomas, particularly in elderly patients. The overall survival rate was comparable to previous studies of this agent." - Anonymous Online Contributor
"There have not been any significant new treatments for lymphoma, b-cell. Only one newer drug, rituximab, has shown promise in treatment. Rituximab is an immunosuppressive drug that specifically targets B cells. It was originally used for chronic lymphocytic leukemia (CLL) but has also seen success against follicular lymphoma and diffuse large B cell lymphoma. Rituximab has shown some promise in treating relapsed or refractory follicular lymphoma." - Anonymous Online Contributor
"The number of patients with lymphoma, B-cell a year in the US was estimated at 53,000, based on the data from the SEER database. This means that 1 in 48 Americans (19%) will get lymphoma, B-cell a year. These numbers do not take into account age or sex." - Anonymous Online Contributor
"Clinical trial enrollment was higher among patients with primary cHL than those without cHL. The reasons for this remain unclear but may reflect current practice patterns. This finding may motivate more patients with cHL to enroll in clinical trials." - Anonymous Online Contributor
"Lymphoma, B cell, is a rare disease with various manifestations. With appropriate management, patients can achieve excellent outcomes; however, the prognosis of untreated patients is poor. Lymphoma, B cell, is a heterogenous disease with a wide variety of morphologies and patterns of expression of molecular markers." - Anonymous Online Contributor